Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 1 shares, a growth of ∞ from the June 30th total of 0 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 1,653 shares, the days-to-cover ratio is presently 0.0 days.
Starpharma Stock Performance
Starpharma stock opened at $4.69 on Wednesday. Starpharma has a 52-week low of $0.67 and a 52-week high of $5.70. The firm has a 50 day moving average price of $4.76 and a two-hundred day moving average price of $3.97.
Starpharma Company Profile
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Featured Stories
- Five stocks we like better than Starpharma
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
